Pharmaceutical quantitation solution guide
September 9th 2025We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created this solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options. This guide covers bio/pharmaceutical quantitative assays from discovery to QA/QC, for large and small molecules. Happy reading!
New Strategies for a Better Glycosylation Profile
January 22nd 2025Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
Mass Information on Charge Variants in Minutes, Not Weeks
August 2nd 2024Explore how an integrated, single platform imaged capillary isoelectric focusing (icIEF)-UV/MS workflow with the Intabio ZT system aims to tackle the challenge of charge heterogeneity profiling with a disruptive strategy that allows for separation, quantitation, and identification of individual charge variants to be achieved in minutes on a single platform.
mAb Characterization Process Innovations
February 8th 2024Earlier assessment of molecules provides valuable insights into the manufacturing developability of molecules, reducing the need for unnecessary experimentation. The Intabio ZT system has the potential to make in-depth characterization of biopharmaceutical product charge variants quicker and more efficient to meet demanding timelines during early-phase clinical development.
Moving SWATH LC–MS Host Cell Protein Analysis into a GMP Environment?
October 6th 2021Wednesday, October 6, 2021 at 12pm EDT | 9am PDT | 5pm BST | 6pm CEST In this webinar, you will learn about the possibility of GMP method transfer for HCP assays leveraging a robust and automated workflow based on combining data-dependent and data-independent mass spectrometry. A study of data from multiple projects over three years demonstrated the robustness and reproducibility of the method.
Characterization of Next Generation Antibody-Drug Conjugates (ADCs) by Mass Spectrometry
March 2nd 2021*Live Date: Tuesday, March 2, 2021 at 11am EST | 8am PST | 4pm GMT | 5pm CET* In this webinar, you will learn how LC-MS has been broadly leveraged to accelerate the development of antibody-drug conjugates (ADCs). *Available On Demand Until March 2, 2022*